ADMA Biologics (ADMA) AI Stock Analysis

• Market Cap: $4.66B
• Dividend Yield: N/A
• Average Volume (3M): 3.26M
• Price to Earnings (P/E): 23.0
• Beta (1Y): 0.87
• Revenue Growth: 27.62%
• EPS Growth: 202.89%
• Country: US
• Employees: 685
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 237,997,770
• 10 Day Avg. Volume: 3,406,507
• 30 Day Avg. Volume: 3,260,260
• PEG Ratio: -0.03
• Price to Book (P/B): 11.45
• Price to Sales (P/S): 9.37
• P/FCF Ratio: 36.31
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $32.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: $21.00 ▲(42.66% Upside)

ADMA Biologics scores well due to its strong financial performance and positive earnings call, which highlight robust revenue growth and strategic initiatives for future expansion. The technical analysis suggests bullish momentum, though caution is advised due to overbought signals. Valuation is reasonable, supporting the overall positive outlook.

ADMA Biologics Business Overview & Revenue Model

Company Description

ADMA Biologics (ADMA) is a biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics. The company operates primarily in the healthcare sector, emphasizing the manufacture of immunoglobulins and related products that are essential for treating immune deficiencies and other serious medical conditions. ADMA's core products include Intravenous Immunoglobulin (IVIG) and subcutaneous immunoglobulin formulations, which are designed to improve the quality of life for patients with compromised immune systems.

How the Company Makes Money

ADMA generates revenue primarily through the sales of its immunoglobulin products, including its flagship product, ASCENIV, which is marketed for the treatment of primary immunodeficiency diseases. The company also derives income from the sale of other plasma-derived therapies, which are distributed through specialty pharmacies and healthcare providers. Key revenue streams include direct product sales, partnerships with healthcare facilities, and contracts with distributors. Additionally, ADMA has engaged in collaborations and strategic partnerships that enhance its market reach and provide financial support for its product development initiatives, contributing to its overall earnings.

ADMA Biologics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

ADMA Biologics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Positive. The current price of 14.72 is below the 20-day moving average (MA) of 19.34, below the 50-day MA of 16.86, and below the 200-day MA of 18.15, indicating a bullish trend. The MACD of 0.72 indicates Positive momentum. The RSI at 60.49 is Neutral, neither overbought nor oversold. The STOCH value of 34.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADMA.

ADMA Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
ADMA	78 Outperform	$4.66B	22.99	63.17%	―	27.62%	202.89%
PTGX	68 Neutral	$5.38B	135.85	7.80%	―	-35.39%	-72.97%
ARWR	57 Neutral	$9.26B	-1,014.29	-0.50%	―	23258.15%	99.12%
IMVT	45 Neutral	$5.38B	-9.43	-95.93%	―	―	-27.70%
MLTX	41 Neutral	$955.69M	-4.02	-54.17%	―	―	-157.74%
ACLX	40 Underperform	$3.70B	-16.32	-47.18%	―	-76.96%	-425.41%

ADMA Biologics Corporate Events

ADMA Biologics Inc. Reports Strong Q3 Earnings Call

ADMA Biologics Inc. Reports Strong Q3 Performance Amid Strategic Initiatives

ADMA Biologics Reports Strong Q3 2025 Financial Results

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company specializing in the manufacturing, marketing, and development of specialty biologics, particularly plasma-derived products for immunodeficient patients. The company has announced its third-quarter 2025 financial results, highlighting a 12% year-over-year increase in total revenue to $134.2 million and a 1% increase in GAAP net income to $36.4 million. Adjusted EBITDA saw a significant rise of 29% to $58.7 million, reflecting strong operational performance.